目的 觀察氣滯胃痛顆粒聯(lián)合雷貝拉唑?qū)Ψ戳餍允彻苎祝≧E）患者胃動(dòng)力調(diào)節(jié)激素以及炎癥因子的影響，并探討相關(guān)的臨床意義。方法 選取2013年2月－2016年2月北京市昌平區(qū)中醫(yī)院收治的RE患者96例，隨機(jī)分為對(duì)照組和觀察組，各48例。對(duì)照組服用雷貝拉唑鈉腸溶片10 mg/次、2次/d，觀察組在對(duì)照組基礎(chǔ)上加用氣滯胃痛顆粒5 g/次、3次/d，均4周為1療程。放射免疫法檢測(cè)胃泌素、胃動(dòng)素表達(dá)，酶聯(lián)免疫法測(cè)定白介素-17（IL-17）和白介素-23（IL-23）表達(dá)。比較兩組治療后有效率和不良反應(yīng)發(fā)生率。結(jié)果 治療前對(duì)照組和觀察組的胃泌素和胃動(dòng)素表達(dá)無(wú)顯著差異，治療后兩組的表達(dá)均顯著升高（P<0.05、0.01），但治療后觀察組的胃泌素和胃動(dòng)素表達(dá)顯著高于對(duì)照組（P<0.05）。治療前對(duì)照組和觀察組IL-17和IL-23表達(dá)無(wú)顯著差異，治療后兩組的表達(dá)均顯著減低（P<0.05、0.01），但治療后觀察組的IL-17和IL-23表達(dá)顯著低于對(duì)照組（P<0.05）。觀察組和對(duì)照組臨床治療有效率分別為93.8%和81.3%，觀察組有效率顯著高于對(duì)照組（P<0.05）。對(duì)照組不良反應(yīng)率為10.4%，觀察組的為8.3%，兩組比較無(wú)顯著差異。結(jié)論 氣滯胃痛顆粒聯(lián)合雷貝拉唑可以改善反流性食管炎患者胃-食管動(dòng)力、抑制炎癥反應(yīng)，療效顯著，且使用安全。

Objective To observe the effect of Qizhi Weitong Granules combined with rabeprazole on gastroesophageal dynamics and inflammatory factors in reflux esophagitis (RE) and explore its clinical significance. Methods Nighty-six RE patients from Changping Chinese Medicine Hospital were selected in this study, which randomly divided into control group (n=48) and observation group (n=48). The control group was given rabeprazole 10 mg/time (2 times/d) for 4 weeks. The observation group was given rabeprazole 10 mg/time (2 times/d) and Qizhi Weitong Granule 5 g/time (3 times/d) for 4 weeks. The gastrin and motilin expression was detected by radioimmunity analysis. The IL-17 and IL-23 was detected by ELISA analysis. The rate of clinic effects and adverse reaction was compared. Results There was no significant difference of gastrin and motilin between the two groups before treatment. After treatment, gastrin and motilin was increased in the two groups (P<0.05, 0.01). However, gastrin and motilin was higher in observation group than that in control group after treatment (P<0.05). There was no significant difference of IL-17 and IL-23 between two groups before treatment. After treatment, IL-17 and IL-23 was decreased in the two groups (P<0.05, 0.01). However, IL-17 and IL-23 was lower in observation group than that in control group after treatment (P<0.05). The rate of clinic effects was 93.8% in observation group, which was better than 81.3% in control group (P<0.05). The rate of adverse reaction was 10.4% in control group and 8.3% in observation group. There was no significant difference between two groups. Conclusion Qizhi Weitong Granules combined with rabeprazole can improve gastroesophageal dynamics and inhibit inflammatory response in RE patients, with significantly clinical effect and safety.